Cantor Fitzgerald Reiterates "Overweight" Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Cantor Fitzgerald has reaffirmed an "overweight" rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) with a target price of $100.00, indicating a potential downside of 6.46% from the previous close. Other analysts have mixed ratings, with two Buy, twelve Hold, and one Sell. The stock remained flat at $106.91, with a market cap of $9.21 billion. Recent insider sales and institutional investments have also been noted. Verona Pharma reported earnings of $0.13 per share, exceeding estimates, with a revenue of $103.14 million for the last quarter.

Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)

According to TipRanks, Brayer is a 3-star analyst with an average return of 4.4% and a 40.98% success rate. Brayer covers the Healthcare sector, focusing on stocks such as United Therapeutics, BioMarin Pharmaceutical, and Alnylam Pharma. Currently, the analyst consensus on Verona Pharma is a Hold with an average price target of $106.22.

Verona Pharma Completes Acquisition and Delisting Process

Verona Pharma has completed its acquisition process, sanctioned by the High Court of Justice of England and Wales on October 6, 2025. Shareholders received cash for their shares, and the company's ADSs were delisted from Nasdaq. The board of directors resigned, and new executives were appointed. Analysts rate VRNA stock as Hold with a $107.00 price target, citing strong revenue growth but noting profitability challenges and high valuations. The current market cap is $9.19B, with a technical sentiment signal of Buy.

Market news: Merck has completed the acquisition of Verona Pharma

Merck Completes Acquisition of Verona Pharma, Adding COPD Drug Ohtuvayre to Portfolio

Merck has completed its acquisition of Verona Pharma, making it a wholly-owned subsidiary. As a result, Verona Pharma’s American Depositary Shares will no longer be traded on the Nasdaq. This acquisition adds Ohtuvayre, a new treatment for COPD, to Merck’s portfolio. Ohtuvayre is the first novel inhaled mechanism for COPD maintenance in over 20 years and has received FDA approval. Merck aims to expand access to this medication and collaborate with Verona Pharma's team to enhance its performance.